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Abstract
This practical atlas aims to help liver and non liver pathologists to recognize
benign hepatocellular nodules on resected specimen. Macroscopic and
microscopic views together with immunohistochemical stains illustrate typical and
atypical aspects of focal nodular hyperplasia and of hepatocellular adenoma,
including hepatocellular adenomas subtypes with references to clinical and
imaging data. Each step is important to make a correct diagnosis. The specimen
including the nodule and the non-tumoral liver should be sliced, photographed
and all different looking areas adequately sampled for paraffin inclusion. Routine
histology includes HE, trichrome and cytokeratin 7. Immunohistochemistry
includes glutamine synthase and according to the above results additional
markers such as liver fatty acid binding protein, C reactive protein and
beta catenin may be realized to differentiate focal nodular hyperplasia from
hepatocellular adenoma subtypes. Clues for differential diagnosis and pitfalls ...
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Abstract
This practical atlas aims to help liver and non liver pa-
thologists to recognize benign hepatocellular nodules on 
resected specimen. Macroscopic and microscopic views 
together with immunohistochemical stains illustrate 
typical and atypical aspects of focal nodular hyperplasia 
and of hepatocellular adenoma, including hepatocel-
lular adenomas subtypes with references to clinical and 
imaging data. Each step is important to make a correct 
diagnosis. The specimen including the nodule and the 
non-tumoral liver should be sliced, photographed and 
all different looking areas adequately sampled for par-
affin inclusion. Routine histology includes HE, trichrome 
and cytokeratin 7. Immunohistochemistry includes glu-
tamine synthase and according to the above results ad-
ditional markers such as liver fatty acid binding protein, 
C reactive protein and beta catenin may be realized to 
differentiate focal nodular hyperplasia from hepatocel-
lular adenoma subtypes. Clues for differential diagnosis 
and pitfalls are explained and illustrated.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: In this paper are illustrated macroscopic and 
microscopic aspects of focal nodular hyperplasia and 
hepatocellular adenoma. These illustrations represent 
typical as well as less usual aspects of these two be-
nign hepatocellular tumors. Microscopic pictures are 
performed using classical routine stains such as HE, 
trichrome or cytokeratin 7 or less usual markers proven 
of great interest to identify focal nodular hyperplasia 
(FNH) such as glutamine synthase or liver fatty acid 
briding protein, C reactive protein or b catenin to iden-
tify hepatocyte nuclear factor 1 alpha mutated hepato-
cellular adenoma (HCA), inflammatory HCA, β-catenin 
mutated HCA respectively. These illustrations combined 
with brief clinical information should be helpful for pa-
thologists for their practice. Indeed if FNH are rather 
frequent tumor easy to recognize, there are difficulties 
when key features are lacking or when features such as 
steatosis or sinusoidal dilatation, features of HCA, are 
present. The great message of this paper is the pos-
sibility to identify HCA subtypes, a key feature for the 
coming years to better manage patients.
Sempoux C, Balabaud C, Bioulac-Sage P. Pictures of focal 
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INTRODUCTION
In the most recent liver pathology textbooks[1-4], the de-
scription of  focal nodular hyperplasia (FNH) and hepa-
tocellular adenoma (HCA) taking into account the new 
classification of  HCA allows to better differentiate FNH 
from HCA and to identify HCA subtypes, but not sur-
prisingly there are few pictures of  these 2 entities by lack 
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of  space.
The aim of  this atlas is to illustrate more extensively 
than in textbooks[1-4] and journals[5-7] the most frequent 
pathological aspects of  FNH and HCA both macro-
scopically and microscopically, using traditional routine 
stainings and more recently described immunohisto-
chemical approach.
It is important to mention that if  these new immuno-
histochemical techniques have allowed the classification 
of  HCA into subtypes by the pathologists, the definite 
criteria to classify HCA relies on molecular analysis[8]. 
The strict correlation between the interpretation of  the 
HCA classification based on the phenotype (macros-
copy, routine techniques and immunohistochemistry) 
versus the genotype defined by the molecular analysis 
has to be strictly performed. In addition, the molecular 
classification is still in progress; therefore some data pre-
sented here should be interpreted cautiously in particular 
regarding the subgroups of  β-catenin mutated HCA 
(β-HCA) and unclassified HCA (UHCA).
FOCAL NODULAR HYPERPLASIA
FNH are frequent hepatocellular nodules. Until recently 
the diagnosis was not always easy[9]. If  the diagnosis is 
certain, resection is not recommended[10]; however, resec-
tion is occasionally performed upon pain, organ compres-
sion, doubt in differential diagnosis with HCA or with 
hepatocellular carcinoma. Using routine histopathological 
techniques [HE, trichrome, cytokeratin 7 (CK7)] the di-
agnosis is certain in more than 80% of  cases. Glutamine 
synthase (GS) staining has the great advantage to confirm 
rapidly and with high confidence the diagnosis[11]. When 
combining all the markers, the accuracy of  the diagnosis 
is close to 100%.
HEPATOCELLULAR ADENOMA
HCA are rare hepatocellular nodules frequently resected 
when their size exceed 5 cm. HCA are divided into sub-
types using molecular markers and immunohistochemis-
try[12]. The most common HCA: HNF1A mutated HCA 
(H-HCA, 35%) and inflammatory HCA (IHCA, 50%) 
can be recognized with some degree of  confidence by 
imaging techniques and by HE[13-15]. GS is a surrogate 
marker to identify β-catenin mutated HCA (β-HCA, 10% 
and β-catenin activated inflammatory HCA, β-IHCA, 
10% of  IHCA)[15,16]. Identification of  β-catenin mutated 
HCA is of  major clinical relevance because of  the highest 
risk of  malignant transformation[17,18]. The mutation can 
be confirmed using β-catenin staining. The absence of  
aberrant nuclear staining is not however an argument to 
refute the diagnosis, because it is often focal[15,16]. When 
GS is difficult to interpret, molecular biology is necessary 
to demonstrate β-catenin mutation in order to confirm 
the diagnosis[8]. When the diagnosis of  H-HCA or IHCA 
is not self-evident on routine stainings, immunostainings 
included liver-fatty acid binding protein (L-FABP), C-re-
active protein (CRP), markers which are useful to identify 
H-HCA (absence of  LFABP) and IHCA (diffuse positiv-
ity of  CRP). The absence of  the above markers identifies 
unclassified HCA (less than 10%). The differential diag-
nosis between FNH and HCA is important as well as the 
identification of  HCA subtypes thought to be of  great 
importance for the present and future management[19-22]. 
Indeed, in the past there has been a great confusion be-
tween FNH and HCA[23,24]. 
Below are figures of  FNH and HCA. For each mac-
roscopic or microscopic pictures, we have given in the 
legend a minimum of  clinical information. In this prac-
tical atlas we have not illustrated HCA with malignant 
transformation.
DIAGNOSIS
To increase the chance to make a correct diagnosis, some 
rules must be respected: the specimen must be carefully 
sliced; photographs should be taken to illustrate necrosis, 
hemorrhage and fibrotic bands; all areas of  interest must 
be sampled as well as the non tumoral liver and the junc-
tion between the nodule and the non tuomral-liver; rou-
tine histology includes HE, trichrome, and CK7; these 
markers may be sufficient to make a diagnosis of  FNH, 
HCA and eventually HCA subtypes. When needed to 
differentiate an FNH from an HCA or to identify HCA 
subtypes, additional immunomarkers may be useful. In 
some occasions all of  them may be useful when there is 
no indication for a specific diagnosis or HCA subtypes: 
it includes LFABP, C reactive protein (CRP), GS and 
β-catenin. Even when all the rules are followed, difficul-
ties in interpretation may occur. First of  all to have to 
check the quality of  the technique; it is not necessary to 
overinterpret doubtful immunohistochemical data. When 
there is no way to interpret satisfactorily the data, one 
is forced to rely on the molecular data. This is why it is 
highly recommended for referral center to freeze material 
(tumor and non tumoral tissue) when their counterparts 
are analysed by routine histology.
RESULTS 
FNH
The macroscopic aspects are presented in Figure 1. Mi-
croscopic typical features on Masson’s Trichrome, GS 
and CK7 immunostainings are presented in Figure 2. 
Microscopic atypical features on Masson’s trichrome and 
GS immunostaining are presented in Figure 3. The other 
microscopic aspects dealing with steatotic, pre-FNH and 
regressing FNH are presented in Figure 4.
HCA
The macroscopic aspects of  different subtypes are pre-
sented in Figure 5.
H-HCA
The microscopic typical and atypical features are present-
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ed in Figures 6 and 7 respectively. The different aspects 
of  LFABP and GS stainings are presented in Figures 8 
and 9 respectively.
Inflammatory HCA 
The typical microscopic aspects are presented in Figures 
10 and 11. The immunohistochemistry is presented in 
Figure 12.
β -IHCA 
Microphotographs are presented in Figures 13-15.
β -catenin 
Micrographs are presented in Figures 16 and 17 showing 
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Figure 1  Focal nodular hyperplasia the macroscopic aspects. A: Man born in 1988; 100 kg/1.95 m; abdominal pain; abnormal liver function tests; magnetic reso-
nance imaging (MRI): liver mass 9.5 cm: Focal nodular hyperplasia (FNH)/hepatocellular adenoma (HCA) (bisegmentectomy in 2009). Fresh specimen: typical aspect 
of FNH: Tan, vaguely plurinodular tumor, non encapsulated, with central stellate scar. This macroscopic aspect is typical and the diagnosis of FNH is evident. The 
diagnosis was confirmed on HE and CK7. B: Woman born in 1951; acute abdominal pain followed by discomfort and pain on abdominal palpation; ultrasound (US): 2 
nodules, largest one 3.5 cm. Magnetic resonance imaging (MRI): FNH (left hepatectomy in 2008). Fixed specimen: plurinodular tumor with thin fibrous bands, non en-
capsulated but well demarcated from surrounding liver parenchyma, with large portal tract at the interface (arrow). The diagnosis of FNH is evident. The diagnosis was 
confirmed on HE and CK7. C: Woman born in 1986; abdominal pain; MRI 2007: FNH 6.4 cm close to the biliary convergence; US in 2000: hemangioma 15 mm; 2004: 
4.5 cm (tumorectomy in 2007). Fresh specimen: pedunculated irregular nodule with eccentric fibrous scar, well demarcated from the surrounding liver. The diagnosis 
of FNH is likely. D: Woman born in 1965; oral contraceptives for 18 years; abdominal pain; imaging (6 cm): FNH [surgery in 2005 (tumorectomy)]. Fresh specimen: 
clear-tan, vaguely plurinodular tumor, without clear-cut fibrous scar. The diagnosis of FNH is not self-evident. The diagnosis was confirmed on HE, CK7 and glutamine 
synthase (GS). E: Woman born in 1961; abnormal liver function tests; liver US: nodule 5.5 cm, MRI and US favors HCA over FNH (segmentectomy Ⅶ in 2009). Fresh 
specimen: irregular cut surface with tan nodules separated by congestive/reddish, atrophic areas. The diagnosis of FNH is unlikely. F: Woman born in 1956; check-up 
for arterial hypertension; liver imaging (2 cm nodule): probable HCA (tumorectomy in 2003) (other nodules were found). Fresh specimen: well-limited, non encapsu-
lated, smooth nodule, with small reddish areas, without any fibrous bands or scar visible. The diagnosis of FNH is unlikely. The diagnosis was confirmed by HE, CK7 
and GS.
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Figure 2  Focal nodular hyperplasia microscopic typical features on Masson’s trichrome, glutamine synthase and CK7 immunostainings. A: Same patient as 
Figure 1C. Glutamine synthase (GS) immunostaining: typical aspect of focal nodular hyperplasia (FNH) with large anastomosed positive areas in a “map-like” pattern[11]. B-D: 
Woman born in 1969; abnormal liver function tests (GGT); ultrasound (US): nodule interpreted as a hemangioma, computed tomography scan and magnetic resonance im-
aging: FNH 8 cm, segment VIII with minor dilatation of the right biliary tree (compression by the tumor). Left lobectomy + segmentectomy Ⅷ in 2002 (other nodule segment 
Ⅱ: 0.5 cm). B, C: GS immunostaining: typical aspect of FNH with anastomosed positive areas often centered by veins (arrowhead) and at distance of fibrous bands (arrows). 
C and D are from 2 serial sections. D: CK7 immunostaining: ductular reaction at the periphery of fibrous bands. E, F: Same patient as Figure 1C. E: Masson’s trichrome - 
fibrous bands surrounding benign hepatocytic nodules of different sizes. F: CK7 immunostaining - prominent ductular reaction at the junction between parenchymal nodules 
and fibrous bands. Typical aspect of FNH.
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Figure 3  Focal nodular hyperplasia microscopic atypical features on Masson’s trichrome and glutamine synthase immunostaining. A, B: Same patient as 
Figure 1E. A: Masson’s trichrome - large areas of sinusoidal dilatation (arrowhead), nearby solid hepatocytic areas (right) with thin, short fibrotic bands. B: Glutamine 
synthase (GS) immunostaining - typical aspect of focal nodular hyperplasia (FNH) with anastomosed positive areas in a “map-like pattern” in the nodular area (right); 
no staining in the sinusoidal dilation area (left). This aspect is very unusual. This nodule should not be interpreted as a mixed tumor (part FNH and part hepatocellular 
adenoma) and should not be called “telangiectatic FNH”[23,24]. A better term could be FNH with major sinusoidal dilatation. C, D: Woman born in 1969, 2003; 2 FNH: 
first hepatic resection (tumorectomy in 2003 for a 7-cm FNH). In 2004, persistence of abdominal discomfort (no change in size of the 7 cm FNH). Right hepatectomy. 
C: Typical GS staining (left); no GS staining in the area of sinusoidal dilatation (right). D: Obvious ductular reaction on the CK7 immunostaining. Although the 2 above 
cases are very rare, FNH with areas of sinusoidal dilatation are seen occasionally. 
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Figure 4  Other aspects (steatotic, pre-focal nodular hyperplasia, regressing focal nodular hyperplasia). A, B: Woman born in 1959; heavy alcohol consump-
tion, tobacco; hepatomegaly, no evidence for cirrhosis on liver function tests, virus negative. Computed tomography scan: nodule 3.5 cm and others (1.5, 0.3 and 0.8 
cm). No firm radiological diagnosis: ?focal nodular hyperplasia (FNH)/hepatocellular adenoma (HCA)/HCC, left hepatectomy in 2001. A: Masson’s trichrome - the 
nodule is composed of benign steatotic hepatocytes separated by fibrous bands. Steatosis is not a rare event in FNH. B: Glutamine synthase (GS) immunostaining - 
anastomosed GS positive areas, favoring the diagnosis of steatotic FNH. The diagnosis of FNH remains doubtful, however. In this case, the diagnoses of HNF1A mu-
tated HCA, inflammatory HCA, β-HCA and β-IHCA were ruled out (specific IHC markers were negative). The diagnosis of unclassified HCA cannot, however, be ruled 
out. Molecular analysis is necessary to confirm the diagnosis. C, D: Woman born in 1950; abdominal pain: gallbladder lithiasis; Magnetic resonance imaging (MRI): 2.5 
cm nodule, probably an HCA. Left hepatectomy plus cholecystectomy in 2000. C: Fixed specimen - subcapsular, not well defined nodule barely visible, clearer than 
the surrounding liver. D: GS immunostaining - the positive perivenular areas are slightly but significantly larger than in the surrounding normal liver; this aspect is inter-
preted as a “pre-FNH” without fibrosis and nodulation. Pre FNH is probably not a rare entity but to-day there is no consensus concerning its denomination[9]. This type 
of lesion has been named in congenital vascular abnormalities such as Rendu-Osler disease. E, F: Woman born in 1948; intrahepatic hemorrhagic rupture of a large 
nodule of segment Ⅶ in 2009. MRI favors HCC, additional 4 nodules known since 2005 and interpreted as FNH. Size of the FNH nodule resected with the HCC has 
decreased significantly. Right hepatectomy (HCC + 1 additional not identified nodule, previously known as FNH). E: Fresh specimen: close to the hemorrhagic HCC, a 
4 cm hard white/brown nodule, under the capsule (arrow), with irregular surface. F: GS immunostaining: limited positive areas (map-like pattern) surrounded by large 
areas of dense fibrous tissue (arrowhead). All these features are interpreted as a regressing FNH. This interpretation needs to be confirmed by additional cases.
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Figure 5  Hepatocellular adenoma macroscopic aspects of different subtypes: A-C: Examples of HNF1A mutated hepatocellular adenoma (H-HCA). A: 
Woman born in 1972; oral contraceptives for 8 years. Discovery of a liver nodule (3.5 cm). No regression after stopping contraceptives. Fear of complications by 
the patient. Left hepatectomy in 2008; fresh specimen: yellowish tumor, clearer than the surrounding liver. The diagnosis of H-HCA is likely but not self-evident. 
The diagnosis was confirmed by immunohistochemistry. B: Woman born in 1974; oral contraceptives for 12 years. Liver nodules discovered by chance on imag-
ing and diagnosis of adenomatosis. Largest nodule 5 cm. Segmentectomy IVb 2006. Other small nodules. One nodule was an focal nodular hyperplasia (FNH). 
Fixed specimen of one nodule: yellowish, clear tumor, non encapsulated, contrasting with the surrounding liver. The diagnosis of H-HCA is likely. The diagnosis 
was confirmed by immunohistochemistry. C: Woman born in 1978. Massive right hepatomegaly discovered in the obstetric department (miscarriage at 6 wk). No 
oral contraception. Right hepatectomy in 2004. Fresh specimen: large irregular, mammillated tumor occupying the whole right liver. This is an exceptional case. 
The diagnosis was confirmed by immunohistochemistry. D-F: Examples of IHCA (D, E) and β-IHCA (F). D: Woman born in 1968; overweight, BMI > 40 kg/m2. Oral 
contraceptives for 18 years. Several nodules detected on imaging. Doubtful diagnosis. Surgical biopsies: HCA. Right hepatectomy in 2008 (largest nodule 10 cm). 
In 2009, another known HCA removed in the left liver (11 cm). Fresh specimen: reddish tumor with congestive areas. The diagnosis of inflammatory HCA (IHCA) 
is likely. The diagnosis was confirmed by immunohistochemistry. E: Woman born in 1956; oral contraceptives for 31 years. Biological abnormalities (inflammatory 
syndrome). CT scan and MRI multiple liver nodules (largest nodule 7 cm) in favor of IHCA. Surgery in 2007: bisegmentectomy Ⅵ-Ⅶ plus 2 tumorectomies. Fresh 
specimen: ill defined tumor with congestive strands. The diagnosis of IHCA is very likely. The diagnosis was confirmed by immunohistochemistry. F: Woman born 
in 1971; liver hemorrhage. Imaging: 5 nodules, largest 8 cm. No oral contraceptives; BMI 20.4 kg/m2. Segmentectomy Ⅲ, Ⅵ, Ⅷ 2007. Fixed specimen: large he-
matoma and a narrow viable tissue at the periphery. No obvious diagnosis. The diagnosis of HCC cannot be ruled out. The diagnosis was confirmed by immuno-
histochemistry. G: Example of β-catenin HCA. Woman born in 1981; one nodule 8 cm discovered by chance. Imaging HCA. Oral contraceptives for 8 years; BMI 
21.1 kg/m2. Right hepatectomy 2005. Fresh specimen: well limited clear nodule. The diagnosis of HCA is likely. H-HCA and IHCA are unlikely. H: Example of HCC 
developed on β-IHCA. Woman born in 1934; intramuscular injection of hormones as contraceptive. Liver nodule interpreted as hemangioma, known for several 
years. Growth of the nodule. Segmentectomy in 2000. Fresh specimen: irregular, multinodular tumor, with a large necrotic and hemorrhagic area ( arrowhead) 
surrounded by a fibrous rim. The diagnosis of HCC is likely. I: Example of unclassified HCA. Woman born in 1983; abdominal pain. Imaging: one nodule 8 cm; no 
final diagnosis. Oral contraceptives for 8 years. BMI 20.2 kg/m2. Right hepatectomy 2007. Fresh specimen: well limited clear nodule with a pale reddish area. The 
diagnosis of HCA is likely. H-HCA and IHCA are unlikely. 
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Figure 6  HNF1A mutated hepatocellular adenoma microscopic typical features. A: Woman born 
in 1955; surgery in 2010 for an HCC (6 cm) developed on a non fibrotic liver. Discovery of another 
small nodule on the surgical specimen. No oral contraceptives; BMI 24.1 kg/m2. HE: typical aspect of 
HNF1A mutated hepatocellular adenoma (H-HCA): nodule with lobulated contours, made of benign 
hepatocytes with diffuse steatosis; some congestive areas ( arrowhead); sharp contrast with non stea-
totic surrounding liver. The diagnosis was confirmed by immunohistochemistry. B, C: Woman born in 
1952; abdominal pain; imaging: nodule 1.8 cm, no firm diagnosis by magnetic resonance imaging. Oral 
contraceptives, 27 years; BMI 22.0 kg/m2. Tumorectomy in 2008. B: Nodule composed of benign, clear 
hepatocytes, sometimes steatotic, separated by thin strands of atrophic hepatocytes (arrow). C: Same 
nodule seen at higher magnification. Although clear hepatocytes are not the hallmark of H-HCA, the 
lobular pattern is very characteristic. It consists of steatotic or clear hepatocytes arranged in a lobular 
pattern separated by tumoral, atrophic, not steatotic hepatocytes. Commonly, arterioles/small arteries 
are seen in this space (not shown on this micrograph). The diagnosis was confirmed by immunohisto-
chemistry.
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Figure 7  HNF1a inactivated hepatocellular adenoma microscopic atypical feature. A, B: Woman born in 1952; abnormal liver function tests; oral contraceptives 
13 years; BMI 25.4; magnetic resonance imaging (MRI): adenomatosis, largest nodule 6 cm. Segmentectomy Ⅳ/Ⅵ in 2001. A: ill defined nodule composed of clear 
hepatocytes, with mild steatosis. B: Same nodule seen at a higher magnification. The normal portal tract from the periphery of non tumoral parenchyma is entrapped 
in the nodule. The diagnosis of HNF1A mutated hepatocellular adenoma (H-HCA) is less evident than in Figure 6B, C. The diagnosis was confirmed by immunohis-
tochemistry. C, D: Woman born in 1950; abnormal liver function tests; imaging: probable FNH 12 cm. Right hepatectomy 2002. HE: proliferation of benign hepatocytes, 
no steatosis, mild sinusoidal dilatation. This is a rare case. The diagnosis of H-HCA cannot be suspected without performing immunohistochemistry. E, F: Woman born in 
1965; past history of cancer. Abdominal pain. Oral contraceptives 10 years, BMI 21 kg/m2. MRI: Adenomatosis, largest nodule 3.9 cm. Segmentectomy and tumorectomy 
in 2011. HE: Proliferation of benign hepatocytes, no steatosis, mild sinusoidal dilatation, numerous ectatic vessels. As above, in this rare case the diagnosis of H-HCA can-
not be suspected without immunohistochemistry, and malignant transformation has to be ruled out.
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Figure 8  HNF1a inactivated hepatocellular adenoma different aspects of liver-fatty acid binding protein staining. A: Same patient as Figure 7C, D. Typical as-
pect: absence of liver-fatty acid binding protein (LFABP) staining in tumor contrasting with normal expression in non tumoral liver (NT). B: Same patient as Figure 7E, F. 
Bands of non tumoral (NT) parenchyma normally expressing LFABP are penetrating within the unstained tumor. Indeed, the growth of HNF1A mutated hepatocellular 
adenoma (H-HCA) is due to the coalescence of several adenomatous liver nodules and it is not rare to find non adenomatous liver lobules squeezed in between. C: 
Woman born in 1962; abdominal pain. Oral contraceptives 25 years; BMI 25 kg/m2. Two liver nodules, largest 3.7 cm. Segmentectomy Ⅴ/Ⅵ (2005). Bands of hepa-
tocytes expressing LFABP within the unstained typical H-HCA. Same comment as above. D: Same patient as Figure 7E, F. LFABP expression in a few perivenular 
hepatocytes, particularly at the periphery of H-HCA, is a frequent observation, as well as a rim of positive hepatocytes at the border. E, F: Woman born in 1967; ad-
enomatosis suspected during coelioscopy for extrauterine pregnancy. Segmentectomy for a 6 cm liver nodule. On HE (E), at distance from the main lesion, the pres-
ence of several steatotic small nodules well identified on LFABP staining (F). This is a very specific and characteristic aspect of H-HCA adenomatosis.
Figure 9  HNF1a inactivated hepatocellular adenoma different aspects of glutamine synthase immunostaining. A: Same patient as Figure 7E, F. There is no 
staining within the lesion, except around some veins, mainly at the borders where liver-fatty acid binding protein staining (not shown) demonstrates intermingled HN-
F1A mutated hepatocellular adenoma (H-HCA) and normal parenchyma areas. It was impossible on HE staining to clearly identify the border of the tumor. B: Woman 
born in 1964; one nodule discovered by chance, 5.5 cm; oral contraceptives 21 years; BMI 18.4 kg/m2. Biopsy: β-HCA. Segmentectomy Ⅷ 2007. Diffuse, moderate 
glutamine synthase (GS) staining, contrasting with normal staining in non tumoral liver in which the GS staining is limited to 1-3 rows of centrilobular hepatocytes. 
Today, in the absence of β-catenin nuclear staining, the significance of this abnormal GS staining in HCA remains unknown and molecular analysis is mandatory to 
search for β-catenin mutations. C, D: Same patient as Figure 7C, D. Heterogeneous, mild staining in tumoral hepatocytes, sometimes arranged in rosettes. The pres-
ence of rosettes is often considered as a criterion suggesting a possible malignant transformation; it may also reflect cholestatic features. Same comment as above: in 
the absence of molecular analysis, it is not possible to conclude and a search for β-catenin mutations is mandatory.
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Figure 10  Inflammatory hepatocellular adenoma typical microscopic aspects. A: Woman born in 1959; adenomatosis discovered by chance. Size of the larg-
est nodule: 11 cm. Oral contraceptives for 23 years; BMI 27.0 kg/m2. Left hepatectomy 2008. HE: typical aspect of an inflammatory hepatocellular adenoma (IHCA) 
with many small inflammatory foci (arrows) dispersed within the tumor, associated with areas of moderate sinusoidal dilation ( arrowhead). In this area, sinusoids are 
dilated, another hallmark of this subgroup. B: Woman born in 1969; abnormal liver function tests. One liver nodule, 12 cm. Oral contraceptives for 16 years; BMI 26.0 
kg/m2. Right hepatectomy 2004. HE: areas of sinusoidal dilatation and pseudo portal tracts with thick walled arteries and inflammatory cells (arrows), hallmarks of 
this subgroup. The diagnosis was confirmed by immunohistochemistry. C: Man born in 1968; abnormal liver function tests. One nodule 12 cm. BMI 30.0 kg/m2. Right 
hepatectomy 2011. HE: prominent inflammatory foci dispersed in the tumor; thick vessels at the border of the HCA (arrow). The diagnosis was confirmed by immu-
nohistochemistry. D: Woman born in 1966; liver nodule, 3.5 cm discovered by chance. No oral contraceptives, BMI 24.5 kg/m2. Right hepatectomy 2004. HE: inflam-
matory foci, areas of sinusoidal dilatation; in this area, tumoral hepatocytes are steatotic. E: Woman born in 1973; overweight. Adenomatosis discovered by chance. 
Largest nodule 7 cm. Biopsy HCA. Tumorectomy Ⅳ, Ⅵ, Ⅶ 2003. HE: ill defined benign hepatocellular tumor (arrow); limited areas of sinusoidal dilatation (arrowhead) 
predominating at the periphery of the tumor. The non tumoral liver is steatotic, a frequent finding in this group of patients. F: Woman born in 1966; abnormal liver 
function tests. Several liver nodules. Biopsy HCA; oral contraceptives for 10 years, BMI 29.6 kg/m2. Left hepatectomy and tumorectomy Ⅳ and Ⅵ, 2007. Masson’s 
trichrome: pseudo portal tracts (arrows) with arteries in fibrous tissue; large areas of steatosis, within the tumor. The tumor is limited by thick arteries and veins from 
the non tumoral liver (NT).
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Figure 11  Inflammatory hepatocellular adenoma typical microscopic aspects. A: Same patient as Figure 10 D. B: Same patient as Figure 10F. HE: thick-walled 
arteries surrounded by inflammatory cells. These pseudo portal tracts are very characteristic of inflammatory hepatocellular adenoma (IHCA). C, D: Woman born in 
1972; oral contraceptives for 19 years. BMI 19.6 kg/m2. One nodule 10 cm discovered by chance. Magnetic resonance imaging: IHCA. Right hepatectomy 2009. HE: 
prominent sinusoidal dilatation. E, F: Same patient as Figure 10F, different tumors. E: HE - tumor ill-defined from the surrounding liver without any inflammation or si-
nusoidal dilatation. F: HE - the histological aspect is different with a more typical aspect of IHCA. Here, thick arteries are surrounded by inflammatory cells and fibrous 
tissue within the hepatocellular proliferation. 
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Figure 12  Inflammatory hepatocellular adenoma immunohistochemistry. A, B: Same patient as Figure 10 F, different tumors. C-reactive protein (CRP): typical 
aspect of inflammatory hepatocellular adenoma (IHCA) with strong and diffuse expression in tumoral hepatocytes, with sharp demarcation from the surrounding non 
tumoral liver (A); more irregular CRP staining with limited areas remaining negative (B); C: Same patient as Figure 10D. CRP is expressed only in hepatocytes. D, E: 
Same patient as Figure 10F. D: Glutamine synthase: no abnormal staining; positivity only in some perivenous hepatocytes at the periphery of the nodule. E: CK7: faint 
staining around pseudo portal tracts, underlining ductular reaction, a common finding in IHCA. F: Same patient as Figure 10A. CK7 highlights the major ductular reac-
tion at the periphery of pseudo portal tracts. 
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Figure 13  β-catenin activated, inflammatory hepatocellular adenoma. A-F: Man born in 1971. BMI 21.6 kg/m2. By chance, discovery of one nodule 6 cm. Imaging: 
focal nodular hyperplasia. Right hepatectomy 2006. A: Fresh specimen: pigmented, irregular tumor. Non tumoral liver is normal. B: HE: Hepatocellular adenoma with 
sinusoidal dilatation and inflammatory infiltrate (on the left); large vessels at the junction with non tumoral liver. C: Diffuse expression of C-reactive protein by tumoral 
hepatocytes, with sharp demarcation from the non tumoral liver. D: Strong and diffuse glutamine synthase (GS) expression contrasting with normal staining of GS in 
adjacent non tumoral liver (in a few pericentrolobular hepatocytes). E: Large areas are positive for CD34, but not  diffuse diffusely; F: Aberrant nuclear and cytoplasmic 
expression of β-catenin in quite numerous hepatocytes.
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Figure 14  β-catenin activated, inflammatory hepatocellular adenoma. A, B: Woman born in 1967. Oral contraceptives 20 years, BMI 20.0 kg/m2. By chance, dis-
covery of one nodule 18 cm. Imaging hepatocellular adenoma (HCA). Segmentectomy IV and V 2005. A: HE: features of inflammatory HCA (IHCA): sinusoidal dilata-
tion, thick vessels, mild inflammation. B: Glutamine synthase immunostaining is abnormal, but faint and heterogeneous with reinforcement around veins. C, D: Woman 
born in 1974; oral contraceptives 13 years. BMI 21.0 kg/m2. By chance, discovery of one nodule 6.5 cm. Imaging IHCA. Segmentectomy Ⅵ and Ⅶ 2009. C: Marked 
but not diffuse CD34 immunostaining. D: Very few tumoral hepatocytes expressed aberrant nuclear β-catenin.
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Figure  15 β-catenin activated, inflammatory hepatocellular adenoma. A-C: Woman born in 1971; liver hemorrhage. No oral contraceptives. BMI 20.4 kg/m2. Im-
aging 5 nodules, largest 8 cm. Segmentectomy Ⅲ, Ⅵ, Ⅷ 2007. A: HE - large arteries at the periphery of the nodule. Mild sinusoidal dilatation in the non tumoral liver 
(NT). B: Abnormal patchy GS staining in one nodule. C: Abnormal homogeneous glutamine synthase (GS) staining in another nodule. D-F: Woman born in 1959; oral 
contraceptives for 21 years. BMI 21.8 kg/m2. Abnormal liver function tests. Imaging: 3 nodules, largest 10 cm. Right hepatectomy 2005. In the three nodules, GS stain-
ing is different but definitely abnormal. D: Homogeneous. E: Extremely faint. F: Patchy GS staining. The difficulty in interpreting GS often comes from the positivity that 
can be found around veins. This perivenular staining is normal when it is strictly limited to 1 or 2 rows of perivenular hepatocytes; the interpretation of a GS staining 
larger than 2 or 3 rows of hepatocytes, even if faint or patchy, remains poorly understood in the absence of molecular analysis.
Figure 16  β-hepatocellular adenoma.. A, B: Man, 16 
years old under androgen treatment for a hematological 
disorder. Imaging: several nodules; tumorectomy of one 
nodule 3 cm. HE: Hepatocellular adenoma (HCA) with 
some glandular arrangements ( arrowhead) and a few 
larger, irregular nuclei (arrow). According to the clinical 
context, the diagnosis of β-catenin is very likely. C, D: 
Woman born in 1953; oral contraceptives for 4 years. 
Danazol one year (endometriosis). BMI 19.5 kg/m2. 
Asthenia. Imaging: one nodule 3 cm. Right hepatectomy 
in 1989. C: HE: Well limited HCA with no features of 
H-HCA, or of IHCA. By default, the diagnosis of β-catenin 
is therefore a possibility. D: Aberrant cytoplasmic and 
nuclear expression of β-catenin in numerous hepatocytes 
confirms the diagnosis of β-HCA; E, F: Woman born in 
1980; oral contraceptives for 12 years. BMI 20.4 kg/m2. 
Abdominal pain. Imaging: one nodule 15 cm: HCA. Right 
hepatectomy 2009. E: HE - numerous vessels within the 
HCA. This aspect seems to be quite characteristic of 
β-HCA and of some unclassified HCA; F: Aberrant ex-
pression of β-HCA in very few hepatocytes confirms the 
diagnosis of β-HCA.
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Figure 17  β-hepatocellular adenoma different types of glutamine synthase immunostaining. A: Same patient as Figure 16C, D. Strong and diffuse expression 
of glutamine synthase (GS) in hepatocellular adenoma (HCA) (left), contrasting with non tumoral liver (positivity in only few pericentrolobular hepatocytes). B-D: Same 
patient as Figure 16 E, F. Strong, heterogeneous (patchy) positivity of GS seen at different magnification, with a reinforcement rim at the periphery of the HCA (the rim 
positivity has no pathological significance). E, F: Woman born in 1986; abnormal liver function tests. Imaging: one nodule 9 cm, HCA. Left hepatectomy 2007. E: HE - 
no specific abnormalities. The presence of numerous vessels is, however, intriguing in this young patient. F: Patchy positivity of GS from mild to strong.
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Figure  18 β-catenin hepatocellular adenoma. A, F: Same patient as Figure 5G. A: HE: Numerous vessels dispersed within the hepatocellular proliferation. B: Quite 
numerous CK7+ cells dispersed within the tumor; some are small, looking like progenitor cells; others are larger as intermediate cells. C, D: Diffuse positivity of CD 34 
within the tumor. E, F: Patchy positivity of glutamine synthase.
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different types of  GS staining and Figure 18.
UHCA
UHCA are still poorly understood entities. However, their 
histological characteristics are worrisome and in many 
aspects in at least 50% of  cases are reminiscent of  b 
catenin HCA. Micrographs are presented in Figures 19 
and 20.
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